Immune-Epidermal Dual Targeting in Psoriasis: Emerging Technologies and Translational Therapeutic Strategies.
Although immune-targeted therapies, particularly agents targeting the IL-23/IL-17 axis, have markedly improved short-term disease control in psoriasis, inadequate responses in a subset of patients and relapse after treatment discontinuation remain unresolved challenges. One possible reason is that immune-centered thera...